Page 2 - Ben Brahim News Today

Positive data on key clinical candidates delivered in 2022 Promising outlook for 2023 as industry interest in therapeutic cancer vaccines and oncolytic viruses gains significant momentum TG4050:New

Study will evaluate the intravenous administration of company’s multi-armed immunotherapy - News - PharmaTimes

In Tunisia, 12 years after the revolution, citizens are still asking, "How do you expect me to make a living?"

The analysis showed a clear benefit for patients with anogenital cancers who received the vaccine plus a checkpoint inhibitor over those who received only a checkpoint inhibitor.

Based on promising progression-free survival (PFS) interim analysis, trial to continue and an optimized number of patients to be randomized in the trial Management to host webcast presentation of

TG4001- Results from the interim analysis of the randomized Phase II trial in HPV-positive anogenital cancers to be released in Q4 2022 TG4050 (myvac platform) - New positive Phase I data presented

Strasbourg, France, and Lund, Sweden, June 28, 2022, 8:00 am CEST – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, and BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), a biotech company focused on th...

LUND, SWEDEN / ACCESSWIRE / June 28, 2022 / BioInvent International (STO:BINV)Lund, Sweden - June 28, 2022 - BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused

Transgene’s Combined General Meeting of May 25, 2022 Strasbourg, France, May 25, 2022, 05:45 p.m. CEST – The Combined Ordinary and Extraordinary General Meeting of Transgene’s shareholders was held today (May 25, 2022) at 10:00 a.m. at the Company’s headquarters (400 boulevard Gonth...

Regulatory News: The Combined Ordinary and Extraordinary General Meeting of Transgene's (Paris:TNG) shareholders was held today (May 25, 2022) at 10:00 a.m. at the Company's headquarters (400 boulevard